Roy E Smith
Roy E Smith
Professor of Medicine
  • :(412) 648-6466

Division of Hematology/Oncology
University of Pittsburgh
School of Medicine
USA

Education

1973-1974 Ohio State University, Columbus, OH Internship, Medical
1974-1976 Ohio State University, Columbus, OH Resident, Medical
1976-1978 Ohio State University, Columbus, OH Fellowship, Hematology- Oncology

 

Biography

Roy E. Smith, MD is a Professor of Medicine at the University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology-Oncology. He is board certified in hematology and medical oncology.After completing his post-doctoral training, Dr. Smith joined the faculty at the Ohio State University (OSU) where he served as the director of the Hematology Fellowship Training Program, the Clinical Coagulation Service, and the OSU Hemophilia Center. Dr. Smith is a former chairman of the Central Investigational Review Board for Cancer Therapy Evaluation Program of the National Cancer Institute and has played a key role in revising its role in the conduct of Cooperative Group Pogram trials.

Research Interest

Colorectal Cancer 
Bleeding and Thrombostic Disorders 

Professional Activities:

Awards And Honors

1979 Research Award, Central Ohio Heart Association                                                              
1985 Citizen Ambassador Program Delegate to Republic of                                                    
1985 South Africa.  Dr. Rolf Barth Delegation on Oncology.
Citizen Ambassador Program Delegate to the People's                                                  
Republic of China.  Dr. Scott Swisher Delegation on
Hematology and Blood Transfusion.
2012 Citizen Ambassador Program Delegate to the People's                                                  
2014 Republic of China.  Dr. Scott Swisher Delegation on

 

Publications

  1. Falko JM, Guy JT, Smith RE, and Mazzaferri EL.  Primary hyperparathyroidism and anemia.  Arch Intern Med 136:887-889, 1976. PubMed PMID: 949188.
  2. Smith RE, Lobuglio AF: An approach to anemia.  Med Opinion April, 1977.
  3. King GW, Halpin JJ, Smith RE, Batley F, Schuller DE.  Cis-dichlorodiammineplatinum (II), methotrexate, bleomycin, and vincristine in head and neck cancer:  A pilot study.  Cancer Treat Rep 63(11-12):1735-1738, 1979. PubMed PMID: 93508.
  4. Custer GE, Briggs BR, Smith RE.  Effect of cefamandole nafate on blood coagulation and platelet function.  Antimicrob Agents Chemother 16(6):869-872, 1979. PubMed PMID: 533268. PMC352969.
  5. Custer GE, Briggs BR, Smith RE.  Cefamandole nafate and blood coagulation.  Ohio State Med J 76(8):517-521, 1980. PubMed PMID: 7402519.
  6. Dewald DL, Briggs B, Smith RE.  Intranasal administration of desmopressin acetate (DDAVP) to hemophiliacs.  Thrombosis Res 18(5):617-622, 1980. PubMed PMID: 6774441.
  7. Schuller DE, King CW, Smith RE, Wilson HE, James AD, Batley F.  Combination therapy protocol for stage III or IV carcinoma of the oral cavity, oropharynx and hypopharynx.  Laryngoscope 90(8):1263-1272, 1980. PubMed PMID: 7401827.
  8. Domen RE, Smith RE, Sagone AL.  Lithium carbonate.  Arch Intern Med 141(2):268, 1981. PubMed PMID: 7458526.
  9. Smith RE Saab GA.  Platelet dysfunction in acute lymphatic leukemia.  Arch Intern Med 141(2):269-270, 1981. PubMed PMID: 6935988.
  10. Smith RE, Briggs BR, Unverferth DV, Leier CV.  Dobutamine induced in inhibition of platelet function.  Int J Clin Pharmacol Res 2(2):89-97, 1982.
  11. Niskanen E, Hess C, Smith R, Quesenberry P.  Cancer trends: A treatment role for autologous bone marrow transplants?  Virginia Med 109(2):107-109, 1982. PubMed PMID: 7036559.
  12. Smith RE.  Adjuvant chemotherapy for breast cancer.  Virginia Med 109(11):767-769, 1982. PubMed PMID: 7180150.
  13. Schuller DE, Wilson HE, Smith RE, Batley F, James AD.  Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx.  Cancer 51:15-19, 1983. PubMed PMID: 6185194.
  14. Wade PM, Mills SE, Read M, Cloud W, Lambert MJ, Smith RE.  Small cell neuroendocrine (oat cell) carcinoma of the breast.  Cancer 52:121-125, 1983. PubMed PMID: 6303551.
  15. Wade PM, Smith RE, Johns ME.  Response of esthesioneuroblastoma to chemotherapy.  Cancer 53:1036-1041, 1984. PubMed PMID: 6362834.
  16. Smith RE.  A practical subcutaneous infusion port system for cancer patients.  Ohio State Med J 81(10):743-746, 1985. PubMed PMID: 4069509.
  17. Smith RE.  Protein C & S deficiency.  Journal of People to People Hematology and Blood Transfusion.  Delegation to the People's Republic of China, Appendix A:84, 1985.
  18. Smith RE.  Hypercoagulability and malignancy.  Journal of People to People Hematology and Blood Transfusion.  Delegation to the People's Republic of China, Appendix A:84, 1985.
  19. Smith RE.  Hypercalcemia and abnormal bone scan patterns.  Arch Intern Med 145:1335, 1985. PubMed PMID: 4015292.
  20. Smith RE, Heilbrun LK, Bottomley RM, Gad-el-Mawla N, Fletcher W.  Therapy of recurrent squamous cell carcinoma of the head and neck using combination vincristine, bleomycin, and methotrexate: A Southwest Oncology Group Study.  Cancer 58:2382-2385, 1986. PubMed PMID: 2429754.
  21. Smith RE.  Hand-mirror-cell variant of B-cell lymphoma with hypercalcemia.  Arch Intern Med, 146(11):2273-2274, 1986. PubMed PMID: 3490835.
  22. Smith RE, Chelmowski MK, Anderson T.  Osteonecrosis in a patient with immune thrombocytopenic purpura.  Am J Hematol 26:97-99, 1987. PubMed PMID: 3631066.
  23. Smith RE.  Dietary fat and breast cancer.  Cancer Detect Prev 10:193-196, 1987. PubMed PMID: 3552222.
  24. Smith RE.  Biochemical detection of recurrent breast cancer.  Cancer Detect Prev 11:303-309, 1988. PubMed PMID: 3292045.
  25. Smith RE, Berg DD.  Coagulation defects in cyclosporine A treated allogeneic bone marrow transplant patients.  Am J Hematol 28:137-140, 1988. PubMed PMID: 3044063.
  26. Smith RE, Chelmowski MK, Szabo EJ: Myelofibrosis.  A Concise Review of clinical and pathologic features and treatment.  Am J Hematol 29:174-180, 1988. PubMed PMID: 3055953.
  27. Smith RE, Santamaria J.  Unexplained bleeding in a patient with mechanical valve prostheses.  Am J Med, 85:748, 1988. PubMed PMID: 3263803.
  28. Smith RE, Berg D, Hansom RM.  Computerized tomography in metastatic evaluation.  Wisc Med J 88(5):25-27, 1989. PubMed PMID:2750180.
  29. Smith RE, Janjan N, Kretzschmar S, Hackbarth D.  The effect of radiation therapy on von Willebrand factor in patients with angiosarcoma.  Radiother Oncol 16(4):297-304, 1989. PubMed PMID:2616816.
  30. Smith RE.  Endobronchial polyp and chronic smoke injury.  Postgrad Med J 65:787-787, 1989. PubMed PMID: 2616409. PMC 2429835.
  31. Smith RE, Stoiber TR.  Acute tumor lysis syndrome in prolymphocytic leukemia.  Am J Med 88:547-548, 1990. PubMed PMID: 2337111.
  32. Rousey SR, Smith RE.  A fatal case of low titer anti-PR cold agglutinin disease.  Am J Hematol 35:286-287, 1990. PubMed PMID: 2239927.
  33. Crawford J, Howard O, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.  N Engl J Med 325(3):164-170, 1991. PubMed PMID: 1711156.
  34. Derfus BA, Csuka ME, Carrera GF, Hanson GA, Smith RE.  Bone remodeling after growth factor and cyclosporin A therapy for aplastic anemia.  J Rheumatol 18(5):738-742, 1991. PubMed PMID: 1865422.
  35. Smith RE, Gottschall JL, Pisciotta AV.  Life-threatening reaction to staphylococcal protein A immunomodulation.  J Clin Apheresis 7:4-5, 1992. PubMed PMID: 1592851.
  36. Smith RE, Thornton D, Allen J.  A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies.  Semin Oncol Vol 22, No 3, Suppl 6, pp 41-46, June, 1995. PubMed PMID: 7597432.
  37. Smith RE, Hussain M, Benedetti J, Weiss G, Schuller D, Ensley J.  Evaluation of 96 hour infusion fluorouracil + cisplatin + alpha interferon in patients with advanced squamous cell carcinoma of the head and neck:  A Southwest Oncology Group study.  Cancer 76:233-1237, October 1, 1995. PubMed PMID: 8630903.
  38. Smith RE, Lew D, Rodriguez G, Taylor S, Ensley J.  Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck, A phase II Southwest Oncology Group Study. Investigat New Drugs 14: 403-407, 1996. PubMed PMID: 9157077.
  39. Schuller DE, Grecula JC, Gahbauer RA, Bauer C, Su JL, Smith RE, Haller JR, Mountain RE, Young DC, Nag S.  Intensified regimen for advanced head and neck squamous cell carcinomas.  Arch Otolaryngol-Head Neck Surg 123:139-144, 1997. PubMed PMID: 9046279.
  40. Smith RE.  The INR: A perspective.  Semin Thromb Hemo 23 (6): 547-550, 1997. PubMed PMID: 9469628.
  41. Hayag-Barin JE, Smith RE, Tucker F.  Hereditary spherocytosis, thrombocytosis and chronic pulmonary emboli.  Case report and review of literature.  Am J Hematol Vol 57 (1):82-84, 1998. PubMed PMID: 9423823.
  42. Schlicht JR, Sunyecz L, Weber RJ, Tabas GH, Smith RE. Reevaluation of a weight-based heparin dosing nomogram: is institution-specific modification necessary?  Ann Pharmacother 31:1454-1459, 1998. PubMed PMID: 9416380.
  43. Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams DM, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B.  Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.  J Natl Cancer Inst 90:1810-6, 1998. PubMed PMID: 9839521.
  44. Smith R, Mamounas E, Wieand S, Colangelo l, Wickerham D.  Randomized clinical trial comparing 5-fluorouracil plus leucovorin and UFT and leucovorin in treatment of patients with stages II and III colon cancer.  An interim analysis. Oncology 13 :( supplement 3) pp. 44-47, 1998.
  45. Smith RE.  The INR: A perspective.  Semin Thromb Hemo 23 (6): 547-550, 1997. PubMed PMID: 9469628.
  46. Hayag-Barin JE, Smith RE, Tucker F.  Hereditary spherocytosis, thrombocytosis and chronic pulmonary emboli.  Case report and review of literature.  Am J Hematol Vol 57 (1):82-84, 1998. PubMed PMID: 9423823.
  47. Schlicht JR, Sunyecz L, Weber RJ, Tabas GH, Smith RE. Reevaluation of a weight-based heparin dosing nomogram: is institution-specific modification necessary?  Ann Pharmacother 31:1454-1459, 1998. PubMed PMID: 9416380.
  48. Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams DM, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B.  A clinical trial to assess the efficacy of adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in patients with Dukes’ Stage B and C colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.  J Natl Cancer Inst 90:1810-6, 1998. PubMed PMID: 9839521.
  49. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.  J Clin Oncol 17:3403-3411, 1999. PubMed PMID: 10550134.
  50. Smith R, Wickerham D.  Sequential versus concurrent administration of hormonal and chemotherapy in primary and metastatic breast cancer.  Semin Br Dis 2:157-166, 1999.
  51. Fisher B, Dignam J, Womark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH.  Tamoxifen for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-24.  Lancet 12:1993-2000, 1999. PubMed PMID: 10376613.
  52. Dignam J, Colangelo L, Tian W, Jones J, Smith R, Wickerham L, Wolmark N.  Outcomes among African-Americans and caucasians in colon cancer adjuvant therapy trials: Findings from the National Surgical Adjuvant Breast and Bowel Project.  J Natl Cancer Inst Nov 17 91:1933-40, 1999. PubMed PMID: 10564677.
  53. Smith R, Bryant J, DeCillis A.  The treatment of patients with node-negative breast cancer: A perspective. Oncology Winter: 13-19, 2000.
  54. Grecula JC, Smith RE, Rhoades CA, Sharma P, Agrawal A, Zhang H, Allen J, Goldman FP, Young D, Schuller DE.  Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck.  Cancer 89:2587-2596, 2000. PubMed PMID: 11135220.
  55. Grecula J, Schuller D, Smith R, Rhoades C, Nag KS, Bauer C, Au J, Young D, Gahbauer R.  Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas.  Cancer Inves 19:127-136, 2001. PubMed PMID: 11296617.
  56. Galanakis DK, Kudryk B, Henschen A, Marchi R, Spitzer S, Rohoza A, Ahadi MZ, Smith R, Nagaswami C, Weisel J.  Anti-fibrinogen IgG from a thrombophilic A?R16C (Fibrinogen Northspring) proband accelerates release of clot bound thrombin by enhancing fibrinolysis: A novel procoagulant mechanism.  NY Acad Sci 936:611-616, 2001.
  57. Smith RE, Anderson S, Lembersky BC, Dimitrov N, Desai A, Kardinal C, Mamounas EP.  Phase II trial of a doxorubicin/docetaxel/ cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP BP-58. Clin Breast Cancer 3:333-340, 2002. PubMed PMID: 12533263.
  58. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yoothers G, Anderson S, Smith R, Wickerham D, Wolmark N.  Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project Experience.  J Natl Cancer Inst 94:852-854, 2002. PubMed PMID: 12048273.
  59. Smith R, Bryant J, Decillis A, Anderson S.  Acute myeloid leukemia and myelodysplastic syndrome following doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The NSABP Experience.  J Clin Oncol 21:1195-1204, 2003. PubMed PMID: 12663705.
  60. Smith R, Good BC.  Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant breast and Bowel Project (NSABP) and others. Endocr-Rel Cancer 10:347-357, 2003. PubMed PMID: 14503912.
  61. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer J, Sinn H, Sittek R, Souchon R, Tulusan A, Volm T, Senn H.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.  J Clin Oncol 21:2600-2608, 2003. PubMed PMID: 12829681.
  62. Smith RE.  A review of selective estrogen receptor modulators and National Surgical Adjuvant Breast and Bowel Project clinical trials.  Semin Oncol 30:4-13, 2003. PubMed PMID: 14613021.
  63. Smith RE.  Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: Review of the literature and of the NSABP experience.  Clin Breast Cancer 4:273-279, 2003. PubMed PMID: 14651772.
  64. Smith RE.   Novel Approaches to the Treatment of Locally Advanced Rectal Cancer. Advances in Colon Cancer 7:11-14, 2003.
  65. Smith RE, Bryant J, DeCillis A, Anderson S, National Surgical Adjuvant Breast and Bowel Project Experience.  Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. Journal of Clinical Oncology 21(7):1195-1204, 2003. PubMed PMID: 12663705.
  66. Dignam JJ, Ye Y, Colangelo L, Smith R, Mamounas EP, Wieand HS, Wolmark N. Prognosis After Rectal Cancer in Blacks and Whites Participating in Adjuvant Therapy Randomized Trials.  Journal of Clinical Oncology 21(3):413-420, February 1, 2003. PubMed PMID: 12560428.
  67. Bear HD, Smith R, Fisher B, Wolmark N, Mamounas EP, Brown A, Bryant J, Wickerham L, Anderson S.  The effect on tumor response of adding sequential preoperative docetaxel (taxotere) to preoperative doxorubicin and cyclophosphamide (AC): Preliminary results from NSABP Protocol B-27.  J Clin Oncol Vol 21, Issue 22 (November), 2003: 4165-4174. PubMed PMID: 14559892.
  68. Smith RE.  Oxaliplatin and capecitabine alternating with FUDR for patients with resected hepatic metastases.  Amer J Oncol Rev 3:8-9, 2004.
  69. Smith RE, Anderson SJ, Lembersky BC, Brown A, Mamounas EP.  Phase II trial of a doxorubicin and docetaxel doublet for locally advanced and metastatic breast cancer: Results from NSABP trial BP-57.  Clin Breast Cancer. 2004 Aug; 5(3):208-15. PubMed PMID: 15335453.
  70. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N.  Randomized Trial of Adjuvant Therapy in Colon Carcinoma: 10-Year Results of NSABP Protocol C-01  J Natl Cancer Inst 96:1128-1132, 2004. PubMed PMID: 15292384.
  71. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N.  Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.  J Clin Oncol. 2005; 23(12):2694-2702. PubMed PMID: 15837984.
  72. Atkins JN, Jacobs SA, Wieand HS, Smith RE, John WJ, Colangelo LH, Vogel VG, Kuebler JP, Cescon TP, Miller BJ, Geyer CE, Wolmark N.  Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Brest and Bowel Project Foundation Research Program.  Clin Colorectal Cancer. 2005: 5(3):181-7. PubMed PMID: 16197621.
  73. Kaufmann M, Hortobagyi G, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer J, Eirmann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M,  Minckwitz G. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. Journal of Clinical Oncology 24(12): 1940-1949  April 20, 2006. PubMed PMID: 16622270.
  74. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Palik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 24:2019-27. PubMed PMID: 16606972.
  75. Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A., Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.  J Clin Oncol 2006. 24:2059-64. PubMed PMID: 16648506.
  76. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seasy TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley SA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.  J Clin Oncol, 2007 25:2198-204. PubMed PMID: 17470851.
  77. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr., Cella D, Smith RE, O’Connell MJ, Costantino JP, Wolmark N.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.  J Clinc Oncol 2007, 25(16): 2205-2211. PubMed PMID: 17470850.
  78. Kuebler JP, Colangelo L, O’Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N.  Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.  Cancer 2007, 110(9):1945-1950. PubMed PMID: 17853393.
  79. Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE , Jr, Costatino JP, Wolmark N.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat. Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial.  J Clin Oncol 2008, 26(12):1965-1971. PubMed PMID: 18332472.
  80. Schwartzman AD, Sethi R, Smith R. Multiorgan Failure in a Patient Treated with the 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Regimen. Clin Colorectal Cancer. 2013 Jun;12(2):136-9. doi: 10.1016/j.clcc.2012.09.005. Epub 2012 Oct 24. PubMed PMID:23098664
  81. Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.  A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2013 Sep; 81(3):416-21. PubMed PMID: 23849982.
  82. Yang ZJ, Costa KA, Novelli EM, Smith RE. Venous Thromboembolism in Cirrhosis. Clin Appl Thromb Hemost. 2014 Mar;20(2):169-78. PubMed PMID: 23076776.
  83. Kumar R, Smith RE, Henry BL. A Review of and Recommendations for the Management of Patients with Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience. J Intensive Care Med. 2014 Mar 25. PubMed PMID: 24668159
  84. Sheth HS, Kumar R, DiNella J, Janov C, Kaldas H, Smith RE. Evaluation of Risk Factors for Rectus Sheath Hematoma. Clin Appl Thromb Hemost. 2014 Oct 7. PubMed PMID: 25294636.
  85. Zhou A, Mehta RS, Smith RE. Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Ann Hematol. 2014 Oct 7. PubMed PMID: 25288377.
  86. Mertz KJ, Buchanich JM, Washington TL, Irvin-Barnwell EA, Woytowitz DV, Smith RE. Chronic Myelogenous Leukemia in Eastern Pennsylvania: An Assessment of Registry Reporting. J Registry Manag. 2015 Spring; 42(1) 9-11. PubMed PMID: 25961786.
  87. Tuchayi AM, Smith RE. Evaluation of Schistocytosis in Patients Treated with Dialysis. J Hematol Thromb. 2015;1(1):4.

 

Autoimmune Journal Flyer